AstraZeneca CEO admits struggle in FDA funding campaign
This article was originally published in Scrip
Executive Summary
David Brennan has admitted that his lobbying for more funding for the US FDA is yet to bear much fruit. Speaking exclusively with Scrip at AstraZeneca's financial results in London, the CEO was frank in his assessment that progress has been slow but he remains confident that he will eventually succeed.